ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1870

Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France

Nicoleta Petrica1, Nathan Cohen1, Maria Pini1, Minjee Park2, Mathieu Rosé3 and Jean-Francois Ricci2, 1Alira Health, Paris, France, 2Alira Health, Basel, Switzerland, 3Alira Health, Barcelone, Spain

Meeting: ACR Convergence 2024

Keywords: Administrative Data, Economics, Health Care, longitudinal studies, Lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients’ quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up to 40% of patients experience depression, and 80% face cognitive dysfunction [1]. These neuropsychiatric symptoms may appear before lupus is diagnosed and independent of disease activity. Depression worsens medication adherence and outcomes [2]. While few international studies address neuropsychiatric lupus’s burden, data on MDD prevalence and associated healthcare costs in France are scarce.

This study evaluates the inpatient and day hospital prevalence, healthcare resource use and costs associated with neuropsychiatric manifestations of lupus between 2018 and 2022 in France.

Methods: Retrospective analyses were conducted using the French national hospital claims database (PMSI, Medical surgical and obstetrics (MSO)[3]). Patients hospitalized for Systemic Lupus Erythematosus (SLE; ICD10 M32.X) and/or Lupus Erythematosus (LE; ICD10 L93.X) and MDD (fatigue, major depressive disorder, or other mood disorders) between January 2018 and December 2021 were included and followed-up until their death or end of study (December 2022). The occurrence of hospitalizations all-cause, for lupus, MDD, dialysis and renal disorders was described and hospital costs estimated.

Results: Out of 27,243 lupus patients identified in hospitals between 2018 and 2021, 799 (3%) had a diagnosis of MDD. Among these, 43% had SLE, 24% had LE, and 33% had both. Most were adults (97%), females (85%), with a mean age of 54 (±18.9) at the time of their first lupus hospitalization. Symptoms included malaise and fatigue (68%), major depressive disorders (30%), and other mood disorders (5%). For 61% of patients, the first MDD hospitalization occurred on average one year before the first lupus hospitalization (1.2 ± 1.3 years). Comorbidities included cardiovascular diseases (33%) and kidney disorders (21%). Sixty-eight percent lived in urban areas, while 13% resided in the most deprived areas. The annual hospitalization rates and costs per patient are detailed in Table 1. The mean annual cost per patient for all-cause hospitalizations was €13,129, with 40% attributed to lupus hospitalizations. Patients averaged two lupus hospitalizations per year, and 50% had at least one MDD-related hospitalization during the follow-up.

Conclusion: This nationwide study brings new evidence on the impact of lupus and the neuropsychiatric manifestations of lupus on the French health care system. Overall, more than half of patients were hospitalized with a diagnosis of MDD during the 4-year follow-up. Yet, these numbers may be underestimated considering that most MDD are treated outside the hospital and/or in psychiatric centers in France (data not reported in PMSI MSO). Additional research is needed to further characterize the impact of MDD management, healthcare resource use and associated costs in patients with lupus and psychiatric manifestations in France, using the specific dataset for psychiatric care available within PMSI.

Supporting image 1

Annual hospitalization rates by type of hospitalizations


Disclosures: N. Petrica: None; N. Cohen: None; M. Pini: None; M. Park: None; M. Rosé: None; J. Ricci: Janssen, 2, Novartis, 2, Roche, 3, UCB, 2.

To cite this abstract in AMA style:

Petrica N, Cohen N, Pini M, Park M, Rosé M, Ricci J. Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/costs-and-healthcare-resource-utilization-associated-with-inpatient-and-day-hospitalizations-of-patients-with-lupus-and-psychiatric-manifestations-in-france/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/costs-and-healthcare-resource-utilization-associated-with-inpatient-and-day-hospitalizations-of-patients-with-lupus-and-psychiatric-manifestations-in-france/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology